Luxembourg-based FORTY51 Ventures raised USD43M in the first close FORTY51 Ventures I.
FORTY51 Ventures is anchored by a strong institutional investor syndicate with Stable Asset Management, as well as the Fischli Family. Seasoned Biotech entrepreneurs and private individuals also participated in the first close of the fund.
FORTY51’s core strategy focuses on company formation and early stage investments in Biotech with geographic emphasis on Switzerland, France and Germany. FORTY51 Ventures will lead or co-lead early rounds (Seed and Series A) of its portfolio which will include both academic and Pharma spin-outs.
In addition, the firm announced its first investment in Mosanna Therapeutics, a newly created company that pursues the development of a small molecule developed by Sanofi S.A. (Paris, France) to address patients’ needs suffering from metabolic obstructive sleep apnea.
The fund is advised by a complementary founding team of three industry veterans, Sara Núñez-García, Sascha Oliver Bucher and Tamás Schweighoffer, who bring a deep network and decades of drug development, transactions and venture expertise.
In addition, Peter van Vlasselaer, Bill Symonds, Jonathan Knowles, Hans Schikan and Darren Ji will support the firm as Industry advisors who will lend deep expertise to the growing family of entrepreneurs. Alan S. Roemer will advise the fund as Strategic Partner in the US.
FinSMEs
21/07/2022